BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 34388391)

  • 21. RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.
    Yoo B; Jordan VC; Sheedy P; Billig AM; Ross A; Pantazopoulos P; Medarova Z
    Sci Rep; 2019 Mar; 9(1):4712. PubMed ID: 30886310
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
    Foucher ED; Ghigo C; Chouaib S; Galon J; Iovanna J; Olive D
    Front Immunol; 2018; 9():1044. PubMed ID: 29868007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.
    Wehrli M; Guinn S; Birocchi F; Kuo A; Sun Y; Larson RC; Almazan AJ; Scarfò I; Bouffard AA; Bailey SR; Anekal PV; Montero Llopis P; Nieman LT; Song Y; Xu KH; Berger TR; Kann MC; Leick MB; Silva H; Salas-Benito D; Kienka T; Grauwet K; Armstrong TD; Zhang R; Zhu Q; Fu J; Schmidts A; Korell F; Jan M; Choi BD; Liss AS; Boland GM; Ting DT; Burkhart RA; Jenkins RW; Zheng L; Jaffee EM; Zimmerman JW; Maus MV
    Clin Cancer Res; 2024 May; 30(9):1859-1877. PubMed ID: 38393682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
    Wei L; Ye H; Li G; Lu Y; Zhou Q; Zheng S; Lin Q; Liu Y; Li Z; Chen R
    Cell Death Dis; 2018 Oct; 9(11):1065. PubMed ID: 30337520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The nanobody targeting PD-L1 and CXCR4 counteracts pancreatic stellate cell-mediated tumour progression by disrupting tumour microenvironment.
    Li Y; Zheng Y; Xu S; Hu H; Peng L; Zhu J; Wu M
    Int Immunopharmacol; 2024 May; 132():111944. PubMed ID: 38581990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
    Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
    Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
    Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
    Liu H; Shi Y; Qian F
    Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
    Takeuchi S; Baghdadi M; Tsuchikawa T; Wada H; Nakamura T; Abe H; Nakanishi S; Usui Y; Higuchi K; Takahashi M; Inoko K; Sato S; Takano H; Shichinohe T; Seino K; Hirano S
    Cancer Res; 2015 Jul; 75(13):2629-40. PubMed ID: 25952647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
    Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
    Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
    Bunt SK; Mohr AM; Bailey JM; Grandgenett PM; Hollingsworth MA
    Cancer Immunol Immunother; 2013 Feb; 62(2):225-36. PubMed ID: 22864396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
    Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
    Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement.
    Liu J; Wang Y; Mu C; Li M; Li K; Li S; Wu W; Du L; Zhang X; Li C; Peng W; Shen J; Liu Y; Yang D; Zhang K; Ning Q; Fu X; Zeng Y; Ni Y; Zhou Z; Liu Y; Hu Y; Zheng X; Wen T; Li Z; Liu Y
    Nat Commun; 2022 Jul; 13(1):4308. PubMed ID: 35879297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
    Principe DR; Narbutis M; Kumar S; Park A; Viswakarma N; Dorman MJ; Kamath SD; Grippo PJ; Fishel ML; Hwang RF; Thummuri D; Underwood PW; Munshi HG; Trevino JG; Rana A
    Cancer Res; 2020 Aug; 80(15):3101-3115. PubMed ID: 32238357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.